Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -211.30% is 70% above its 5-year average of -707.47%, near the high end of its 5-year range (-205830.00%–54.55%).
0.76% below its 12-month average of -209.71%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -181.38%.
EBITDA MARGIN
-211.30%
EBITDA MARGIN AVG TTM
-209.71%
EBITDA MARGIN AVG 3Y
-21140.18%
EBITDA MARGIN AVG 5Y
-707.47%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.76%
CURRENT VS 3Y AVG
+99.00%
CURRENT VS 5Y AVG
+70.13%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
ARS Pharmaceuticals, Inc.
Market Cap
$426.13M
EBITDA Margin
-211.30%
TTM Avg
-209.71%
3Y Avg
-21140.18%
5Y Avg
-707.47%
Market Cap
$426.64M
EBITDA Margin
-4.75%
TTM Avg
-133.22%
3Y Avg
-117.53%
5Y Avg
-82.53%
Market Cap
$425.21M
EBITDA Margin
0.24%
TTM Avg
-1.36%
3Y Avg
-6.49%
5Y Avg
-5.53%
Market Cap
$424.75M
EBITDA Margin
-1867.60%
TTM Avg
-990.65%
3Y Avg
-608.01%
5Y Avg
-2572.38%
Market Cap
$430.46M
EBITDA Margin
-232.13%
TTM Avg
-495.69%
3Y Avg
-578.57%
5Y Avg
-532.48%
Market Cap
$419.61M
EBITDA Margin
-189.54%
TTM Avg
-258.01%
3Y Avg
-315.18%
5Y Avg
-540.94%
Market Cap
$414.70M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$412.48M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | $426.13M | -211.30% | -209.71% | -21140.18% | -707.47% |
| Tilray Brands, Inc. (TLRY)vs › | $426.64M | -4.75% | -133.22% | -117.53% | -82.53% |
| NeoGenomics, Inc. (NEO)vs › | $425.21M | 0.24% | -1.36% | -6.49% | -5.53% |
| Prothena Corporation plc (PRTA)vs › | $424.75M | -1867.60% | -990.65% | -608.01% | -2572.38% |
| Editas Medicine, Inc. (EDIT)vs › | $430.46M | -232.13% | -495.69% | -578.57% | -532.48% |
| Senseonics Holdings, Inc. (SENS)vs › | $419.61M | -189.54% | -258.01% | -315.18% | -540.94% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $414.70M | N/A | N/A | N/A | N/A |
| Tectonic Therapeutic, Inc. (TECX)vs › | $437.20M | N/A | N/A | N/A | N/A |
| MapLight Therapeutics, Inc. (MPLT)vs › | $412.48M | N/A | N/A | N/A | N/A |
| Strata Critical Medical, Inc. (SRTA)vs › | $412.30M | -7.84% | -9.54% | -19.72% | -25.08% |
Gross Margin
73.9%
EBITDA Margin
-211.3%
Operating Margin
-212.9%
Net Margin
-184.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -181.38% |
| 2026-03-31 | -263.43% |
| 2025-12-31 | -146.15% |
| 2025-09-30 | -156.43% |
| 2025-06-30 | -301.17% |
| 2025-03-31 | -462.77% |
| 2024-12-31 | 54.55% |
| 2024-09-30 | -1050.63% |
| 2024-06-30 | -3064.40% |
| 2023-06-30 | -205830.00% |
| 2023-03-31 | -93465.00% |
| 2022-09-30 | -3504.23% |
| 2022-06-30 | -1365.84% |
| 2022-03-31 | -1063.20% |
| 2021-12-31 | -630.37% |
| 2021-09-30 | -1063.26% |
| 2021-06-30 | -210.09% |
| 2021-03-31 | -210.09% |
